Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug

Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug

Publication: Mol Pharm
Software: GastroPlus®

The objective of this study was to assess the impact of observed in vitro dissolution rate differences on in vivo pharmacokinetics for two enteric-coated bead formulations...

The biowaivers extension for BCS Class III drugs: the effect of dissolution rate on on the bioequivalence of BCS Class III IR drugs predicted by computer simulation

The biowaivers extension for BCS Class III drugs: the effect of dissolution rate on on the bioequivalence of BCS Class III IR drugs predicted by computer simulation

Authors: Tsume Y, Amidon GL
Publication: Mol Pharm
Software: GastroPlus®

The Biopharmaceutical Classification System (BCS) guidance issued by the FDA allows waivers for in vivo bioavailability and bioequivalence studies for immediate-release...

In Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters

In Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters

Publication: Drug Metab Dispos
Software: ADMET Predictor®

Predicting major clearance pathways of drugs is important in understanding their pharmacokinetic properties in clinical use, such as drug-drug interactions and genetic...

Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects

Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects

Publication: Clin Pharmacol Ther

Intravenous (IV) iron is used to treat iron-deficiency anemia in patients with chronic kidney disease (CKD). Ferumoxytol is a novel iron formulation administered rapidly as two IV boluses of 510 mg each. In this placebo-controlled, double-blind...

Improving productivity with model-based drug development: an enterprise perspective

Improving productivity with model-based drug development: an enterprise perspective

Authors: Grasela TH, Slusser R
Publication: Clin Pharmacol Ther

The productivity of the pharma enterprise has fallen, as evidenced by a decline in regulatory submissions and less commercial success.

Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data

Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data

Publication: J Pharmacokinet Pharmacodyn
Software: GastroPlus®

The aim of this study was to evaluate a strategy based on a physiologically based pharmacokinetic (PBPK) model for the prediction of PK profiles in human using in vitro...

Optimizing the Performance of In Silico ADMET General Models According to Local Requirements: MARS Approach. Solubility Estimations As Case Study

Optimizing the Performance of In Silico ADMET General Models According to Local Requirements: MARS Approach. Solubility Estimations As Case Study

Publication: J Chem Inf Model
Software: ADMET Predictor®

The quality of in vitro data used to build in silico absorption, distribution, metabolism, and toxicity (ADMET) models is, in many cases, inconsistent.

In Silico Prediction of Aqueous Solubility: The Solubility Challenge

In Silico Prediction of Aqueous Solubility: The Solubility Challenge

Publication: J Chem Inf Model
Software: ADMET Predictor®

The dissolution of a chemical into water is a process fundamental to both chemistry and biology. The persistence of a chemical within the environment and the effects of a chemical...

Exposure-response analyses of tigecycline tolerability in healthy subjects

Exposure-response analyses of tigecycline tolerability in healthy subjects

Publication: Diagn Microbiol.Infect.Dis

Tigecycline exposure (area under the concentration-time curve [AUC((0-infinity))] and maximum serum concentration [C(max)]) and first occurrence of nausea and vomiting were evaluated in 136 healthy subjects after...

Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data

Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data

Publication: AAPS J
Software: GastroPlus®

Accurate predictions of human pharmacokinetic and pharmacodynamic (PK/PD) profiles are critical in early drug development, as safe, efficacious, and "developable" dosing...

The use of gastrointestinal intubation studies for controlled release development

The use of gastrointestinal intubation studies for controlled release development

Authors: Sutton SC
Publication: Br J Clin Pharmacol
Software: GastroPlus®

This review describes clinical results of gastrointestinal intubation studies of eight controlled release (CR) candidates under development during the 1990s and offer

Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients

Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients

Publication: J Clin Pharmacol

Linezolid (Zyvox), belonging to oxazolidinone antibiotics, is commonly used for the treatment of patients infected with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.

Role of physiological intestinal water in oral absorption

Role of physiological intestinal water in oral absorption

Authors: Sutton SC
Publication: AAPS J
Software: GastroPlus®

Water volume has impact when the compound has low aqueous solubility. For example, the absorption of compounds with a Biopharmaceutics Classification System...

Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data

Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data

Publication: AAPS J
Software: GastroPlus®
Division: PBPK

The aim of this study was to demonstrate the value of mechanistic simulations in gaining insight into the behaviors of modified release (MR) formulations in vivo and...